Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma
Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a challenging subtype of head and neck cancer that traditionally has been associated with poor prognosis and high morbidity due to the limitations of conventional treatments such as surgery, radiation, and chemotherapy. Immune checkpoint inhibitors ha...
Saved in:
| Main Authors: | Pandiselvi Ravi, Shyamaladevi Babu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004965 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution Experience
by: Tony Z. Zhuang, et al.
Published: (2025-01-01) -
NEW OPPORTUNITIES FOR IMMUNE THERAPY IN PATIENTS WITH DISSEMINATED RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
by: A. M. Mudunov, et al.
Published: (2017-06-01) -
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
by: Antonio Omuro
Published: (2022-08-01) -
Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review
by: Beata Mayer, et al.
Published: (2025-12-01) -
Immune checkpoint inhibitors in pediatric hematologic malignancies
by: I. V. Gribkova
Published: (2023-05-01)